Article
Illudin S inhibits p53-Mdm2 interaction for anticancer efficacy in colorectal cancer
30 Dec 2024
Abstract excerpt
The impairment of the p53 pathway was once regarded as inadequately druggable due to the specificity of the p53 structure, its flat surface lacking an ideal drug-binding site, and the difficulty in reinstating p53 function. However, renewed interest in p53-based therapies has emerged, with promising approaches targeting p53 and ongoing clinical trials investigating p53-based treatments across various cancers....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.